MARKET WIREReuters • 3h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
Why MXCT Stock advanced +1.17% Today — RQD Quant Desk Flash
$1.73 +1.17% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.73
MaxCyte Inc. (MXCT) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $178.5M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.73 (+0.02%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-12.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MXCT)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (30/100 Composite)
🔍 WHY MXCT SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+9/20 pts (30% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (30% of score)
FRED Regime × Technicals: 93% of 52W Range • RSI-14 at 65.4 (BULLISH MOMENTUM)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$1.01+28.7% Next Q
22
Q2 (-2Q)Grade E$1.30+7.7% Next Q
25
Q3 (-1Q)Grade E$1.40+23.6% Next Q
27
CurrentGrade E$1.73-9.6% Hist 90D α
30
Trajectory: E (22) → E (30)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a MXCT Turnaround Squeeze
While MXCT currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.26) and Max Pain ($1.82) forces dealer call-delta covering toward $1.90.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $MXCT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MXCT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why MXCT Stock advanced +1.17% Today — RQD Quant Desk Flash
MaxCyte Inc. (MXCT) advanced +1.17% to $1.73, trading at 93% of its 52-week range ($0.64 – $1.81). Stretched risk/reward at current multiples (-27% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 93% of its 52-week range ($0.64 – $1.81) with RSI-14 at 65.4 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.73 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 127.9% gross margin and $0 annual free cash flow.
Live MXCT Headlines & Catalysts
MARKET WIRECNBC • 5h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 5h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 6h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 7h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 8h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 9h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 9h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MXCT)
- ✓Walkthrough of MXCT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
MXCT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +96.59%📐 HORIZONTAL RANGE
2026-10-30O $1.71H $1.73L $1.50C $1.73VOL 963.6K
RES: $2.01SUP: $0.83SMA50: $1.26SMA200: $1.06
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
MXCT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -5.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on MXCT today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for MXCT. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MXCT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MXCT)
Health Care Rank #942 of 1016
⚔️ NRC vs MXCT Full Matrix →
1. Head-to-Head Health Care Peer Comparison (MXCT vs. NRC, OABI, ONMD, ABSI)
Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, MaxCyte Inc. (MXCT) ranks #942 by composite RQD confidence (30/100, grade E) and #592 by equity capitalization ($178.5M). Within this direct 5-issuer industry benchmark cohort, NRC leads on earnings valuation at 44.8x trailing P/E, while NRC leads on capital efficiency and profitability with 21.0% ROIC and — gross margin. NRC currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with MXCT at 30/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MXCT
ACTIVE
MaxCyte Inc. | E | 30/100 | — | 96.0% | -27.1% | +1.17% | $178.5M | Benchmark Subject |
| NRC NRC Health | C | 65/100 | 44.8x | — | 21.0% | +0.09% | $519.6M | /nrc-vs-mxct → |
| OABI OmniAb Inc. | D- | 38/100 | — | — | -22.6% | -0.95% | $760.4M | /oabi-vs-mxct → |
| ONMD OneMedNet Corp (Class A) | E | 29/100 | — | -30.0% | -35.0% | -2.02% | $26.3M | /onmd-vs-mxct → |
| ABSI Absci Corporation | D | 45/100 | — | — | -35.0% | +1.85% | $2.08B | /absi-vs-mxct → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001287098In its most recent audited fiscal period (FY2025, filed 2025-12-31), MaxCyte Inc. (MXCT) reported GAAP revenue of $21.0M (-5.7% vs. FY2024 revenue of $22.2M , and +7.5% cumulative change since FY2023) , GAAP net income of -$44.6M, operating cash flow of -$34.4M, and free cash flow of -$36.2M (-23.6% YoY). On the balance sheet, MXCT closed FY2025 with $202.5M in total assets against $0 in total debt (Altman Z-Score: 1.52, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $21.0M | -$44.6M | -$34.4M | -$36.2M | $202.5M | — |
| FY2024 (FY) | 2024-12-31 | $22.2M | -$41.1M | -$27.6M | -$29.3M | $239.5M | — |
| FY2023 (FY) | 2023-12-31 | $19.5M | -$37.9M | -$21.7M | -$21.7M | — | — |
3. MXCT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs MXCT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, MaxCyte Inc. (NASDAQ: MXCT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $1.73 (+1.17% 1D, market cap $178.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, MXCT ranks #942 in composite RQD confidence.
How does MXCT compare to NRC and OABI in the Health Care sector?
Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), MXCT carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -27.1%. By comparison, NRC (NRC Health) holds a C grade (65/100 RQD, P/E 44.8x, ROIC 21.0%, cap $519.6M) and OABI (OmniAb Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -22.6%, cap $760.4M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for MXCT?
Per MXCT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001287098), MaxCyte Inc. generated $21.0M in revenue (-5.7% YoY), -$44.6M in net income, and -$36.2M in free cash flow against $202.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is MXCT trading relative to its 50-day, 200-day, and 52-week technical levels?
MXCT last traded at $1.73 (+1.17% on volume of 1,142,252 shares), positioning the stock +37.30% above its 50-day simple moving average ($1.26) and +63.21% above its 200-day simple moving average ($1.06). Across its 52-week range of $0.64 to $1.81, MXCT sits at the 93.2% percentile with a 14-day RSI of 65.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($1.51 to $1.95).
MXCT Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is MXCT stock moving today?
Why MXCT Stock advanced +1.17% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-27% return on capital) under elevated 10-year interest-rate pressure.